Access! 2022 Featured Speaker: Marty Makary, M.D., MPH

Dr. Marty Makary is a New York Times bestselling author and physician and health policy expert at the Johns Hopkins University School of Medicine. He will bring his insights into the future of health care.

Register Now

Dr. Mart Makary

Congress Needs to Hear From You!

Lawmakers are actively considering prescription drug reforms included in the Build Back Better Act (H.R. 5376) that would undermine patient access to affordable FDA-approved biosimilar medicines. Tell your Senator not to put your medicines at risk!

Take Action!

2021 U.S. Generic and Biosimilar Medicines Savings Report

The report proves that the promise of biosimilars is coming to fruition. As patient access to lower-cost biosimilars grew in 2020, savings skyrocketed.

Learn More

Biosimilars are a prescription for better health.

Biosimilars could lead to over $130 billion in savings by 2025, giving 1.2 million patients access to needed medicines.

Learn More

Access! 2022

Plan to join us in person for the first time since 2019 in Orlando, FL!  Sign up before January 31, 2022 to receive $260 off full-pass registration.

Register Today

secure our meds white paper

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.


Browse our Resources

Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.


Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

FDA Biosimilars Approvals

Find an up-to-date list of FDA approved biosimilars and launches.

Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
failure to launch white paper

Recent Tweets

Proposals included in #BuildBackBetter undermine the progress and promise of future #biosimilar savings, particularly for employers and patients in commercial health insurance markets.

Learn more in our latest blog post:

Load More...